Speiser, D. Smith, J. Lee, P. Schaed, S. Pullarkat, V.
Dendritic Cell Immunotherapy
Lee, K. Salio, M. Le Bon, A. Lanzavecchia, A.
Dendritic Cells in Clinics
Fujii, S. Hermans, I. Palmowski, M. Schuler-Thurner, B. Martin-Fontecha, A. Itano, A.
RESTORING IMMUNE FUNCTION
Multivalent Dendritic Cell Vaccine ｜ Tokyo Cancer Clinic
Whole Body Hyperthermia. Peptide Therapy. Share this article :. Comments are closed. Contact A Specialist Today Fill out my online form. Abstract Although the introduction of stem cell transplantation and novel agents has improved survival, multiple myeloma MM is still difficult to cure. Keywords: Multiple myeloma, Dendritic cells, Immunotherapy. Open in a separate window. Critical points for improving cancer immunotherapy using dendritic cells in cancer patients.
Idiotype-pulsed DCs Idiotype Id protein secreted by MM cells presents in processed form on the MM cell surface and is considered a tumor-specific antigen.
Whole tumor antigen-loaded DCs Cancer immunoediting permanently allows a tumor to escape antitumor immunity. Tumor antigens to load onto DCs A good tumor antigen candidate should present a broad tumor-specific fingerprint, the possibility to form MHC class I-peptide complex, ease of preparation, and reduction of immune suppression. Regulation of the tumor suppressive microenvironment Immunomodulatory drugs IMiDs , such as thalidomide, lenalidomide, and pomalidomide, are currently prescribed for MM patients and can reverse the immunosuppressive effect by down-regulation of regulatory T cells Tregs and myeloid-derived suppressor cells MDSCs.
References 1. Cancer immunotherapy comes of age. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Tumoricidal activity of human dendritic cells. Trends Immunol. Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma. Clin Exp Immunol. Generation of multiple peptide cocktail-pulsed dendritic cells as a cancer vaccine. Methods Mol Biol. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients.
Cancer Res. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med.
- Modern Methods in Crop Protection Research.
- Epigenetic and Transcriptional Architecture of Dendritic Cell Development!
- The Death of Hitler: The Full Story with New Evidence from Secret Russian Archives!
- Top 10 Cape Town and the Winelands (Eyewitness Top 10 Travel Guides).
- Evolutionary Psychology: Alternative Approaches;
- Ensuring national biosecurity : Institutional Biosafety Committees!
- Multivalent Dendritic Cell Vaccine.
Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth.
Cellular immunotherapy using dendritic cells against multiple myeloma. Korean J Hematol. J Immunol. Eur J Immunol. Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp Clin Cancer Res. Dickkopf-1 DKK1 is a widely expressed and potent tumor-associated antigen in multiple myeloma.
Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Cancer Immunol Immunother. Novel epitope evoking CD antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders. Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders.
A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates. Leuk Lymphoma.
- Levitation: What It Is, How It Works, How to Do It (Mind, Body, Knowledge)!
- You are here.
- Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic.
- Remember me to Harlem : the letters of Langston Hughes and Carl Van Vechten, 1925-1964.
- The Laws Concerning the So-Called Professional and Habitual Criminals;
Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. Successful cross-presentation of allogeneic myeloma cells by autologous alpha-type 1-polarized dendritic cells as an effective tumor antigen in myeloma patients with matched monoclonal immunoglobulins. Ann Hematol. Dendritic cells loaded with myeloma cells pretreated with a combination of JSI and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in vitro.
Exp Hematol. Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.
Nat Med. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy. Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia.